INVATE LIMITED
Company number 04949747 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Score: C+ (Stable but Under Observation)
Explanation: INVATE LIMITED is a patient that has recently recovered from a severe financial hemorrhage but remains in a fragile state. While the return to profitability in 2024 is a positive vital sign, the company's overall financial body mass (net assets) is very low relative to its size, and its circulatory system (cash flow) is under significant pressure. The business is currently relying on the life support of its parent company's cross-guarantee, meaning it is stable but requires close monitoring.
Key Vital Signs
1. Temperature (Profitability): Warming Up * Reading: The patient suffered a severe chill in 2023 with a loss of £212,474, but the fever has broken. In 2024, the company returned to a healthy temperature with a profit of £70,181. * Interpretation: This is a encouraging sign of recovery, indicating that the core business operations can generate value when conditions are right.
2. Blood Pressure (Liquidity): Strained but Functional * Reading: Current Assets of £1,600,738 against Current Liabilities of £1,384,871 gives a Current Ratio of approximately 1.16:1. * Interpretation: The company can cover its short-term debts, but the margin is slim. The financial blood pressure is elevated; any disruption to cash inflows could cause immediate distress.
3. Pulse (Cash Flow): Weakening * Reading: Cash at bank has dropped from £260,778 in 2023 to £106,161 in 2024. Looking historically, cash was £792,741 in 2015 and £669,982 in 2020. * Interpretation: The patient's pulse is getting weaker. The business is haemorrhaging cash reserves, which limits its ability to respond to emergencies or fund growth without external borrowing.
4. Body Mass (Net Worth): Underweight * Reading: Net assets have recovered from a negative £11,310 in 2023 to a positive £58,871 in 2024. However, this is a shadow of the £951,223 net assets reported in 2020. * Interpretation: The patient has lost a dangerous amount of weight over the last four years. While no longer technically insolvent, the financial cushion is dangerously thin.
5. Cholesterol (Debtors vs. Cash): High Blockage Risk * Reading: Debtors account for a massive £1,204,094 of the £1,600,738 in Current Assets. * Interpretation: The company's financial arteries are clogged with money owed by customers rather than liquid cash. If these debtors fail to pay, the company's liquidity will suffer a heart attack.
Diagnosis
The financial data reveals a business that survived a near-fatal event in 2023 but is still in the recovery ward. The most concerning symptom is the "material uncertainty" explicitly noted in the going concern statement. The directors admit that forecasting is "judgemental and difficult to predict" and could be "subject to significant variation." This is the financial equivalent of a patient with an unpredictable condition—they are stable for now, but a sudden shock could be critical.
The company is heavily dependent on the "life support" of its parent company, eQuality Solutions Group Limited, through a cross-guarantee. While the parent has indicated it will make funds available, this means INVATE LIMITED is not currently standing on its own two feet. Furthermore, the balance sheet is bloated with debtors (£1.2m). If the company cannot collect these debts efficiently, it will not be able to service its £1.38m in current liabilities without further parental assistance or borrowing.
Recommendations
- Lower Financial Cholesterol (Improve Debt Collection): The most urgent treatment is to convert debtors into cash. Implement stricter credit control and collection procedures to clear the £1.2m blockage and improve cash flow without relying on external borrowing.
- Rest and Recuperate (Rebuild Reserves): The £70,181 profit must be retained in the business to rebuild net assets. Do not extract funds via dividends until the patient's financial body mass (net assets) has returned to a healthier, historic level (e.g., the £500k+ range seen in prior years).
- Monitor Vitals Closely (Cash Flow Forecasting): Given the admission that forecasts are "judgemental," management must perform rigorous, weekly cash flow forecasting. This is the financial stethoscope that will detect any relapse before it becomes terminal.
- Review External Dependencies: While the parent company guarantee provides comfort, the business should aim to wean itself off this life support. Management should focus on creating a standalone operational model that can sustain itself without relying on group funding.